Omicron BA .2（B.1.1.529.2）：极有可能成为下一个主要变体
Omicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variant
摘要：
SARS冠状病毒2型（SARS-CoV-2）的Omicron变异株在自然选择的作用下，迅速取代Delta变异株成为优势变异株。Omicron有三个谱系或亚变体，BA.1（B.1.1.529.1）、BA.2（B.1.1.529.2）和BA.3（B.1.1.529.3）。其中，BA.1是目前流行的亚变体。BA.2与BA.1共有32个突变，但有28个不同的突变。BA.3与BA.1和BA.2共享其大部分突变，除了一个。发现BA.2能够令人震惊地重新感染最初被Omicron BA.1感染的患者。一个重要的问题是，BA.2或BA.3是否将成为一个新的占主导地位的“令人关切的变体”。目前，还没有关于BA.2和BA.3的实验数据报道。我们构建了一个新的基于代数拓扑的深度学习模型，该模型使用数万个突变和深度突变数据进行训练，以系统地评估BA.2和BA.3的感染性，疫苗突破能力和抗体抗性。我们对所有主要变体，即Alpha、Beta、Gamma、Delta、Lambda、Mu、BA.1、BA.2和BA.3的比较分析揭示，BA.2的传染性分别是BA.1和Delta的1.5倍和4.2倍。它逃避当前疫苗的能力也分别比BA.1和Delta高出30%和17倍。因此，我们预计Omicron BA.2将成为下一个主导变体。我们预测，与Omicron BA.1一样，BA.2也将严重损害大多数现有mAb，但葛兰素史克开发的sotrovimab除外。
英文摘要：
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, which favors the variant with higher infectivity and stronger vaccine breakthrough ability. Omicron has three lineages or subvariants, BA.1 (B.1.1.529.1), BA.2 (B.1.1.529.2), and BA.3 (B.1.1.529.3). Among them, BA.1 is the currently prevailing subvariant. BA.2 shares 32 mutations with BA.1 but has 28 distinct ones. BA.3 shares most of its mutations with BA.1 and BA.2 except for one. BA.2 is found to be able to alarmingly reinfect patients originally infected by Omicron BA.1. An important question is whether BA.2 or BA.3 will become a new dominating "variant of concern". Currently, no experimental data has been reported about BA.2 and BA.3. We construct a novel algebraic topology-based deep learning model trained with tens of thousands of mutational and deep mutational data to systematically evaluate BA.2's and BA.3's infectivity, vaccine breakthrough capability, and antibody resistance. Our comparative analysis of all main variants namely, Alpha, Beta, Gamma, Delta, Lambda, Mu, BA.1, BA.2, and BA.3, unveils that BA.2 is about 1.5 and 4.2 times as contagious as BA.1 and Delta, respectively. It is also 30% and 17-fold more capable than BA.1 and Delta, respectively, to escape current vaccines. Therefore, we project that Omicron BA.2 is on its path to becoming the next dominating variant. We forecast that like Omicron BA.1, BA.2 will also seriously compromise most existing mAbs, except for sotrovimab developed by GlaxoSmithKline.
机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。
